Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 8/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KLK1 | P06870 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049724 | 0.92 | CHRM3 (0.46) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL1631722 | 0.89 | CHRM3 (0.40) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3401374 | 0.85 | MGLL (0.47) | MGLLPTGDR2FAAH | |
| SCHEMBL1632744 | 0.81 | CHRM3 (0.43) | CHRM3MGLLACKR3KLKB1KLK1 | |
| SCHEMBL4049340 | 0.78 | MGLL (0.43) | CHRM3MGLLPTGDR2CCR1FAAH | |
| SCHEMBL3399340 | 0.78 | MGLL (0.43) | MGLLPTGDR2FAAH | |
| SCHEMBL3395625 | 0.78 | CHRM3 (0.49) | CHRM3MGLL | |
| SCHEMBL1631726 | 0.76 | CYP2E1 (0.40) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL4966502 | 0.76 | CHRM3 (0.39) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL1362389 | 0.76 | MGLL (0.41) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149447-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149447-A1 | Novel M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRNA3 | CYP2E1 4480/4885CYP3A4 3457/4885CYP2A6 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.